Treatment Considerations for Bispecific Antibodies and Unmet Needs in MM
The expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.
BCMA Bispecific T-Cell Engagers in the Treatment of MM
Nausheen Ahmed, MD, gives an overview of BCMA bispecific T-cell engagers used in the treatment of multiple myeloma.
MM: CAR T-Cell Therapy vs Bispecific T-Cell Engagers
Experts on multiple myeloma discuss the mechanism of action and adverse events for teclistamab and compare CAR T-cell therapy with bispecific T-cell engagers (BiTEs).
CAR T-Cell Therapy in the Treatment of Multiple Myeloma
The expert panel discusses CAR T-cell therapy options and treatment considerations for patients with multiple myeloma.
Patient Profile 3: A 73-Year-Old with MM Treated with CAR T and Teclistamab
Al-Ola Abdallah, MD, presents the case of a patient with multiple myeloma treated with CAR T-cell therapy and teclistamab.
CAR T-Cell Therapy in Transplant-Ineligible Patients with MM
Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.
Treatment Considerations for Transplant-Ineligible Patients with MM
The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.
MAIA Trial: DRd vs Rd in Transplant-Ineligible Patients with MM
Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.
Patient Profile 2: A 79-Year-Old with Multiple Myeloma
The expert panel presents the case of a patient with multiple myeloma and discusses evaluating transplant eligibility in patients with MM.
Experts Spotlight Some of The ‘Biggest Concerns’ In Multiple Myeloma
The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.
Maintenance Therapy Considerations for Standard- and High-Risk MM
Experts on multiple myeloma offer clinical insights on treatment options and considerations for patients with standard- and high-risk multiple myeloma.
Measuring Treatment Response Following Induction Therapy in Patients with MM
Nausheen Ahmed, MD, discusses the measurement of treatment response following induction therapy in patients with multiple myeloma.
Features of High-Risk Multiple Myeloma and Clinical Trial Landscape
The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.
Role of Transplant in Multiple Myeloma
Clinical experts examine the role of transplant in multiple myeloma and discuss key clinical trials and the impact of adding daratumumab to triplet therapy.
Key Updates from the GRIFFIN Trial in Multiple Myeloma
Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.
Patient Profile 1: A 45-Year-Old with Transplant-Eligible Multiple Myeloma
A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.
